A 28-Day Study of Diclazuril in the Treatment of Cryptosporidiosis in Patients With AIDS
28 Day Protocol for the Treatment of Cryptosporidiosis in AIDS Patients With Diclazuril (R64,433)
2 other identifiers
interventional
N/A
1 country
3
Brief Summary
To evaluate the safety and efficacy of diclazuril capsules as a treatment for cryptosporidial related diarrhea in AIDS patients who have been treated in the double-blind study # JRD 64,433/1101 and have relapsed, or de-novo patients who have been diagnosed with cryptosporidial related diarrhea and who meet the inclusion and exclusion criteria of this protocol.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
3 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
November 2, 1999
CompletedFirst Posted
Study publicly available on registry
August 31, 2001
CompletedJune 24, 2005
July 1, 1990
November 2, 1999
June 23, 2005
Conditions
Keywords
Interventions
Eligibility Criteria
You may qualify if:
- Concurrent Medication:
- Allowed:
- Zidovudine (AZT).
- Didanosine (ddI) allowed but discouraged, must have been stabilized on a constant dose for 3 weeks or more.
- Aerosolized pentamidine.
- Nystatin for control of oropharyngeal infections. Nystatin must not be taken within two hours of diclazuril.
- Ganciclovir therapy only for CMV retinitis is permitted if the patient has been treated for at least 4 weeks prior to study entry and is stable on the drug.
- Loperamide may be taken if patient has been on long term loperamide prior to study entry but should not be started during the course of this protocol.
- Patients must have the following:
- Written informed consent given after the purpose and nature of the study, as well as the possible adverse effects related to the study drug, have been explained.
- Be willing and able to return for all subsequent weekly visits and the two week visit post completion of therapy (follow-up).
- Prior Medication:
- Allowed:
- Diclazuril.
You may not qualify if:
- Co-existing Condition:
- Patients with the following conditions or symptoms are excluded:
- Uncontrolled vomiting.
- Estimated survival less than 28 days.
- Other treatable enteric pathogens must be treated and eradicated prior to study entry.
- Concurrent Medication:
- Excluded:
- Amphotericin B.
- Other antibiotics or antiprotozoal drugs.
- Other investigational agents.
- Trimethoprim/sulfamethoxazole.
- Antifungal medications except nystatin.
- Ganciclovir for other than Cytomegalovirus (CMV) retinitis.
- Antidiarrheal agents other than patients on long term loperamide prior to study entry.
- Patients with the following are excluded:
- +7 more criteria
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Janssen, LPlead
Study Sites (3)
Bellevue Hosp / New York Univ Med Ctr
New York, New York, 10016, United States
Cornell Univ Med Ctr
New York, New York, 10021, United States
Saint Luke's - Roosevelt Hosp Ctr
New York, New York, 10025, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Purpose
- TREATMENT
- Sponsor Type
- INDUSTRY
Study Record Dates
First Submitted
November 2, 1999
First Posted
August 31, 2001
Last Updated
June 24, 2005
Record last verified: 1990-07